Literature DB >> 10079097

MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.

J Gosling1, S Slaymaker, L Gu, S Tseng, C H Zlot, S G Young, B J Rollins, I F Charo.   

Abstract

The earliest recognizable atherosclerotic lesions are fatty streaks composed of lipid-laden macrophages (foam cells). Circulating monocytes are the precursors of these foam cells, but the molecular mechanisms that govern macrophage trafficking through the vessel wall are poorly understood. Monocyte chemoattractant protein-1 (MCP-1), a member of the chemokine (chemotactic cytokine) family, is a potent monocyte agonist that is upregulated by oxidized lipids. Recent studies in hypercholesterolemic mice lacking apo E or the low-density lipoprotein receptor have suggested a role for MCP-1 in monocyte recruitment to early atherosclerotic lesions. To determine if MCP-1 is critically involved in atherogenesis in the setting of elevated physiological plasma cholesterol levels, we deleted the MCP-1 gene in transgenic mice expressing human apo B. Here we report that the absence of MCP-1 provides dramatic protection from macrophage recruitment and atherosclerotic lesion formation in apo B transgenic mice, without altering lipoprotein metabolism. Taken together with the results of earlier studies, these data provide compelling evidence that MCP-1 plays a critical role in the initiation of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079097      PMCID: PMC408147          DOI: 10.1172/JCI5624

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B.

Authors:  S G Young; S J Bertics; L K Curtiss; D C Casal; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

Review 2.  Chemokines.

Authors:  B J Rollins
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

3.  Synthetic low and high fat diets for the study of atherosclerosis in the mouse.

Authors:  P M Nishina; J Verstuyft; B Paigen
Journal:  J Lipid Res       Date:  1990-05       Impact factor: 5.922

4.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

Authors:  S D Cushing; J A Berliner; A J Valente; M C Territo; M Navab; F Parhami; R Gerrity; C J Schwartz; A M Fogelman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses.

Authors:  E M Rubin; B Y Ishida; S M Clift; R M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

6.  Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B.

Authors:  S G Young; R S Smith; D M Hogle; L K Curtiss; J L Witztum
Journal:  Clin Chem       Date:  1986-08       Impact factor: 8.327

7.  Quantitative assessment of atherosclerotic lesions in mice.

Authors:  B Paigen; A Morrow; P A Holmes; D Mitchell; R A Williams
Journal:  Atherosclerosis       Date:  1987-12       Impact factor: 5.162

8.  Variation in susceptibility to atherosclerosis among inbred strains of mice.

Authors:  B Paigen; A Morrow; C Brandon; D Mitchell; P Holmes
Journal:  Atherosclerosis       Date:  1985-10       Impact factor: 5.162

9.  Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47.

Authors:  S G Young; J L Witztum; D C Casal; L K Curtiss; S Bernstein
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

10.  Genetic analysis of murine strains C57BL/6J and C3H/HeJ to confirm the map position of Ath-1, a gene determining atherosclerosis susceptibility.

Authors:  B Paigen; D Albee; P A Holmes; D Mitchell
Journal:  Biochem Genet       Date:  1987-08       Impact factor: 1.890

View more
  168 in total

Review 1.  Gene targeting of chemokines and their receptors.

Authors:  D M Slattery; N Gerard; C Gerard
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Viral antichemokines: from pathogenesis to drug discovery.

Authors:  P M Murphy
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

3.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 4.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 6.  Inflammation in atherosclerosis and diabetes mellitus.

Authors:  Jorge Plutzky
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

7.  NAD(P)H oxidase-dependent regulation of CCL2 production during retinal inflammation.

Authors:  Wenbo Zhang; Modesto Rojas; Brenda Lilly; Nai-Tse Tsai; Tahira Lemtalsi; Gregory I Liou; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

8.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice.

Authors:  Dennis Bruemmer; Alan R Collins; Grace Noh; Wei Wang; Mary Territo; Sarah Arias-Magallona; Michael C Fishbein; Florian Blaschke; Ulrich Kintscher; Kristof Graf; Ronald E Law; Willa A Hsueh
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  A Novel ASK Inhibitor AGI-1067 Inhibits TLR-4-Mediated Activation of ASK1 by Preventing Dissociation of Thioredoxin from ASK1.

Authors:  Shuhui Zheng; Lingli Long; Yonghao Li; Yuxia Xu; Zhang Jiqin; Weidong Ji; Wang Min
Journal:  Cardiovasc Pharm Open Access       Date:  2015-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.